Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction: a sweet added benefit?

Isla S. Mackenzie, Thomas M. MacDonald (Lead / Corresponding author)

Research output: Contribution to journalEditorialpeer-review

1 Citation (Scopus)

Abstract

This editorial refers to ‘Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial’, by W. Doehner et al., https://doi.org/10.1093/eurheartj/ehac320.
Original languageEnglish
Pages (from-to)3447-3449
Number of pages3
JournalEuropean Heart Journal
Volume43
Issue number36
Early online date8 Aug 2022
DOIs
Publication statusPublished - 21 Sept 2022

Fingerprint

Dive into the research topics of 'Serum uric acid lowering with empagliflozin in heart failure with reduced ejection fraction: a sweet added benefit?'. Together they form a unique fingerprint.

Cite this